Page 99 - TD-4-3

Tumor Discovery Sorafenib induces MVPs in NSCLC

hepatocellular carcinoma-bearing mouse model. Oncotarget. 53. Riess JW, Jahchan NS, Das M, et al. A phase iia study
2016;7(51):85450-85463. repositioning desipramine in small cell lung cancer and
other high-grade neuroendocrine tumors. Cancer Treat Res
doi: 10.18632/oncotarget.13398 Commun. 2020;23:100174.
51. Giovannetti E, Labots M, Dekker H, et al. Molecular doi: 10.1016/j.ctarc.2020.100174
mechanisms and modulation of key pathways underlying
the synergistic interaction of sorafenib with erlotinib in 54. Kachler K, Bailer M, Heim L, et al. Enhanced acid
non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des. sphingomyelinase activity drives immune evasion and
tumor growth in non-small cell lung carcinoma. Cancer Res.
2013;19(5):927-939.
2017;77(21):5963-5976.
doi: 10.2174/1381612811306050927 doi: 10.1158/0008-5472.Can-16-3313
52. Li J, Wang S, Su ZF, Yuan Y. Synergistic effects of sorafenib in 55. Hasan H, Sohal IS, Soto-Vargas Z, et al. Extracellular vesicles
combination with gemcitabine or pemetrexed in lung cancer released by non-small cell lung cancer cells drive invasion
cell lines with K-ras mutations. Contemp Oncol (Pozn). and permeability in non-tumorigenic lung epithelial cells.
2016;20(1):33-38. Sci Rep. 2022;12(1):972.
doi: 10.5114/wo.2016.58499 doi: 10.1038/s41598-022-04940-6

Volume 4 Issue 3 (2025) 91 doi: 10.36922/TD025110019